Suprachoroidal Injection of Triamcinolone Acetonide in Resistant Diabetic Macular Edema, CRVO, Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema Following Pars Plana Vitrectomy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

EARLY_PHASE1

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-12-01

Study Completion Date

2025-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prospective interventional study on 60 eyes of resistant diabetic macular edema and central retinal vein occlusion that will receive suprachoroidal injection of Triamcinolone Acetonide (SCTA).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy of Formulated Posterior Sub Tenon Triamcinolone in Macular Edema Secondary to Non-Ischemic Retinal Vein Occlusions

NCT05345808

Retinal Vein Occlusion

COMPLETED NA

Suprachoroidal Injection of Triamcinolone Acetonide for Management of Diabetic Macular Edema

NCT04069780

Safety Efficacy

UNKNOWN NA

Custom Needle Preparation for Suprachoroidal Steroid Injection (One Year Results)

NCT05496530

Diabetic Macular Edema Vogt Koyanagi Harada Disease Retinal Vein Occlusion

UNKNOWN NA

The Use of Suprachoroidal Triamcinolone Acetonide to Treat Macular Edema in Retinal Vein Occlusion

NCT05038072

Macular Edema Retinal Vein Occlusion

COMPLETED NA

Effectiveness Of Suprachoroidal Injection In Diabetic Macular Edema

NCT06449768

Diabetic Macular Edema

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* Prospective non randomized interventional study on 60 eyes of 40 patients with previously diagnosed macular edema secondary to type 1 or 2 diabetes mellitus and 60 eyes with central retinal vein occlusion will be included.
* The study will be conducted from January 2021 to June 2021.
* For transition to suprachoroidal injection of Triamcinolone Acetone (TAAC) a diagnosis of resistant DME is required.
* Inclusion criteria:

Patients fulfilling one or more of the following criteria will be considered to have resistant diabetic macular edema (DME) after at least 3 consecutive monthly anti vascular endothelial growth factor (VEGF) injections in the previous 6 months: central macular thickness greater than 300 μm by spectral-domain optical coherence tomography (SD-OCT), reduction of retinal thickness by less than 10% of baseline retinal thickness, or suboptimal visual improvement (failure to gain at least 3 lines on the Snellen chart).

* The subjects included in the research will undergo the following tests and investigations:

1. Visual acuity testing (uncorrected and best corrected).
2. Intra ocular pressure (IOP) by applanation tonometry.
3. Anterior segment examination by slit lamp
4. Posterior segment examination by indirect ophthalmoscope and 78 D lens
5. Spectral domain Optical coherence tomography (OCT).
6. Ocular fundus photography and fluorescein angiography.
* Exclusion criteria will be:

1. Previous intraocular surgery (except cataract surgery done more than 6 months before the study).
2. Coincident retinal pathology as choroidal neovascular membrane and age related macular degeneration.
3. Previous laser photocoagulation.
4. Intravitreal injection of triamcinolone acetonide.
5. Prior ocular inflammation.
6. The presence of retinal degeneration.
7. Patients who didnot complete 6 months of follow up

Injection technique:

Preoperative preparation:

1. Preoperative control of (Diabetes Mellitus)DM is essential before injection.
2. Informed consent was obtained according to the ethical committee after discussing extensively with each patient about the benefits, risks and possible side effects of the procedure .
3. The patient was prepared by topical fluoroquinolone eye drops (Moxifloxacin hydrochloride 0.5% Vigamox ,Alcon, USA) 4 times daily for three days before injection.

All patients were dilated before suprachoroidal injection of Triamcinolone Acetonide (SCTA) and indirect ophthalmoscope was placed at hand to examine fundus after injection.

We used 30 gauge 1cc insulin syringe. Other dispensable included 24 gauge intravenous branula. Needle was withdrawn from branula and branula was cut in such a way that only 1000um of insulin syringe was exposed from the edge of branula. 0.1 ml (4 mg ) of Triamcinolone Acetonide (TAAC) will be injected.

Post operative care:

After the injection topical antibiotic drop was applied (Moxifloxacin hydrochloride 0.5% Vigamox, Alcon, USA) and the eye was patched for several hours.

After surgery patients were instructed to administer antibiotic drop four times daily for 3 days .

* Privacy of the patients must be guaranteed ,the data acquired from the participants will stay confidential through:

1. Putting a code number to every patient, with hiding the patient's name.
2. Photographing faces will not be needed.
3. The results of the research will be only used in scientific aim.
* Any unexpected risks like subconjunctival hemorrhage, syncope, vitreous hemorrhage, retinal detachment and endophthalmitis appeared during the course of the research will be cleared to the participants and the ethical committee on time.

Medical care will be carried out to complications like syncope, subconjunctival hemorrhage and surgical treatment by pars plana vitrectomy will be done in case of occurrence of vitreous hemorrhage, retinal detachment or endophthalmitis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Retinal Edema

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

cases of resistant diabetic macular edema and central retinal vein occlusion

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

code number will be given for each participant

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

resistant diabetic macular edema and central retinal vein occlusion

* Prospective non randomized interventional study on 60 eyes of 40 patients with previously diagnosed macular edema secondary to type 1 or 2 diabetes mellitus will be included.
* The study will be conducted from January 2021 to June 2021.
* For transition to suprachoroidal injection of TAAC a diagnosis of resistant DME is required.

Cases with recent onset central retinal vein occlusion less than 2 months duration will be included

Group Type EXPERIMENTAL

Triamcinolone Acetonide 40Mg/Ml Inj,Susp_#1

Intervention Type DRUG

suprachoroidal injection of the drug in cases of resistant diabetic macular edema and central retinal vein occlusion

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Triamcinolone Acetonide 40Mg/Ml Inj,Susp_#1

suprachoroidal injection of the drug in cases of resistant diabetic macular edema and central retinal vein occlusion

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

30 gauge syringe with 24 gauge cannula

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients fulfilling one or more of the following criteria will be considered to have resistant DME after at least 3 consecutive monthly anti VEGF injections in the previous 6 months:
* Central macular thickness greater than 300 μm by spectral-domain optical coherence tomography (SD-OCT).
* Reduction of retinal thickness by less than 10% of baseline retinal thickness.
* Suboptimal visual improvement (failure to gain at least 3 lines on the Snellen chart) and patients with recent onset central retinal vein occlusion less than 3 months.

Exclusion Criteria

* Previous intraocular surgery (except cataract surgery done more than 6 months before the study).
* Coincident retinal pathology as choroidal neovascular membrane and age related macular degeneration.
* Previous laser photocoagulation.
* Intravitreal injection of triamcinolone acetonide.
* Prior ocular inflammation.
* The presence of retinal degeneration.
* Patients who didnot complete 6 months of follow up

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes